Retatrutide is an investigational triple agonist still in active Phase 3 obesity development under Eli Lilly's J1I-MC-GZBJ master protocol, with no MHRA or EMA marketing authorisation as of 2026 [6][7]
Use Nooms Insurance Checker to find out if you qualify
Ozempic is officieel geregistreerd voor de behandeling van diabetes type 2
In preclinical and ex vivo models, GLP-1R agonism has been linked to augmented glucose-dependent insulin secretion, suppressed glucagon release from pancreatic alpha cells, and delayed gastric emptying
For a full 20-week protocol that includes initiation, escalation, and maintenance, most researchers need three to five 20mg vials depending on their chosen titration speed
Richard Sadove is a board-certified plastic surgeon with over 35 years of experience